Targeting IAPs in Leukaemias using the Smac-mimetic drug Birinapant

使用 Smac 模拟药物 Birinapant 靶向白血病中的 IAP

• 批准号: nhmrc : GNT1081376
• 负责人: A/Pr Andrew Wei
• 金额: $ 93.25万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-iaps-leukaemias-drug-birinapant/1345399
• 关键词: Targeting; IAPs; Leukaemias; using; Smac

Acute Myeloid Leukaemia (AML) is an aggressive blood cancer. Overall, less than 50% of AML patients are cured. This project evaluates a new drug, Birinapant, in the treatment of AML. Our research will define the AMLs that best respond to Birinapant, and discover combined therapies that will overcome drug resistance. Thus, this project will lead the way towards a clinical trial of Birinapant in AML, focusing on patients who benefit the most and treatments that increase numbers of who may respond.

急性骨髓性白血病（AML）是一种侵袭性血癌。总体而言，不到50%的AML患者治愈。该项目评估了一种新药Birinapant治疗AML的效果。我们的研究将确定对Birinapant反应最好的AML，并发现克服耐药性的联合疗法。因此，该项目将引领Birinapant在AML中的临床试验，重点关注受益最多的患者和增加可能应答人数的治疗。